TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00679952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed suction drainage of pancreatic duct
Description: A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: natural drainage of pancreatic duct
Description: Natural drainage group
Study: NCT03280004

Intervention type: DRUG
Intervention: Moxifloxacin Hydrochloride and Sodium Chloride Injection
Description: Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
Study: NCT05402644

Intervention type: PROCEDURE
Intervention: hepatectomy
Description: Liver resection

Intervention type: PROCEDURE
Intervention: hepatectomy
Description: Liver resection
Study: NCT02160392

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
Study: NCT02669472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Intervention
Description: Intervention sites received regularly-scheduled, discount, fresh F\&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F\&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F\&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
Study: NCT02007603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Amoxicillin / clavulanic acid
Description: Patients receive amoxicillin / clavulanic acid due to clinical necessity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin / sulbactam
Description: Patients receive ampicillin / sulbactam due to clinical necessity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blooddraws for pharmacokinetic profiling
Description: Blood will be sampled at multiple timepoints during multiple hemodialysis sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blooddraws for pharmacokinetic profiling
Description: Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
Study: NCT06197061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RAMS
Description: The robotic arms were oriented from the caudal direction. Dissection was begun circumferentially at 1.0 cm above the peritoneal reflection. The rectum was mobilized outside the longitudinal muscle layer, with the anatomical plane farther away from Denonvillier's fascia and the nerve plexus anterior or lateral to the rectum. The mobilization of the rectum reached 4-7 cm into the pelvis. After the robot was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAMS
Description: The mesentery of the colon was separated by laparoscopy with the vessel of the pull-through bowel preserved. Under the rectal peritoneal reflex, close to the rectal wall separate with the electric hook, the anterior wall of the rectum was separated to the bladder neck or the posterior wall of the vagina. The posterior wall of the rectum can be separated down to 1cm above the dentate line. After the laparoscopy was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the laparoscopic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
Study: NCT04244929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using standard anterior approach.
Study: NCT03480724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Google Cardboard VRA
Description: Intervention was randomized and shuffled.
Study: NCT04244929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using standard anterior approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining
Description: Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice
Description: Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
Study: NCT02611635

Intervention type: DRUG
Intervention: VKA: Warfarin (Waran)
Description: VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: DRUG
Intervention: NOAC: Rivaroxaban (Xarelto, BAY59-7939)
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: DRUG
Intervention: NOAC: Dabigatran etexilate
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: DRUG
Intervention: NOAC: Apixaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: DRUG
Intervention: NOAC: Edoxaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: DRUG
Intervention: NOAC: Lixiana
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study: NCT01815229

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tracheal lavages
Description: tracheal lavages obtained during endotracheal intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheal lavages
Description: tracheal lavages obtained during endotracheal intubation.
Study: NCT03905863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natrox® Oxygen Wound Therapy
Description: A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
Study: NCT04337411

Intervention type: OTHER
Intervention: Follow-up assessments
Description: Longitudinal evaluation of recovery

Intervention type: OTHER
Intervention: Follow-up assessments
Description: Longitudinal evaluation of recovery
Study: NCT01300182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Description: The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional post-operative physical therapy exercises and rehabilitation.
Study: NCT04176185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunological tablet
Description: For daily administration (1 tablet per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For daily administration (1 tablet per day)
Study: NCT02601924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Benzocain (Master-Dent, Monroe, NC)
Description: Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Benzocain (Master-Dent, Monroe, NC)
Description: Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
Study: NCT03480724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Rift VRA
Description: Intervention was randomized and shuffled.
Study: NCT02402998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 50 mg/daily.
Study: NCT02601924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical pressure massage
Description: Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical pressure massage
Description: Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
Study: NCT00568555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Naltrexone
Description: 3-4.5mg Naltrexone once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose Naltrexone
Description: 3-4.5mg Naltrexone once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - sugar pill
Description: Placebo pill once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar pill
Description: Placebo pill once daily
Study: NCT04357457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almitrine
Description: Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous glucose 5% during 5 days
Study: NCT02354703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (0.33 mg) bid+ BBCET counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (0.33 mg) bid+ BBCET counseling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + BBCET counseling
Study: NCT02010151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAD-CPR
Description: When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
Study: NCT00380042

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cortical Stimulation
Description: Cortical stimulation of prefrontal cortex
Study: NCT02354703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + BBCET counseling
Study: NCT00380042

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham stimulation
Study: NCT02804841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol -Vitamin D3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo -gel capsule containing no vitamin D.
Study: NCT01600625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral minocycline hydrochloride treatment
Description: Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
Study: NCT03495778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Granola
Description: 50.5 Test Granola

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Granola
Description: 54.3 Control Granola
Study: NCT03160794

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]DCFPyL PET/MRI scan
Description: PET/MRI imaging using the radiotracer, \[18F\]DCFPyL

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
Study: NCT02161692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: High dose carboplatin
Study: NCT00700167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine
Description: The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.
Study: NCT02888496

Intervention type: DRUG
Intervention: tocilizumab
Description: 3 monthly IV infusions in PMR patients
Study: NCT00375401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment A
Description: Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment B
Description: Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
Study: NCT02678559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tee measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tee measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flotrac measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flotrac measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clearsight measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clearsight measurement
Study: NCT01645943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiogram
Description: Routine coronary angiogram and revascularization if indicated
Study: NCT03433612

Intervention type: OTHER
Group type: OTHER
Intervention: Classic Intercristal Line Technique
Description: Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique.

Intervention type: OTHER
Group type: OTHER
Intervention: Novel SAIL Technique
Description: Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique.
Study: NCT04084119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypopressive abdominal exercise
Description: Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general strengthening exercise
Description: Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
Study: NCT01906944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Bupivacaine is a local anaesthetic drug belonging to the amino amide group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Bupivacaine is a local anaesthetic drug belonging to the amino amide group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone is a long-acting synthetic corticosteroid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone is a long-acting synthetic corticosteroid.
Study: NCT01492998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guggulsterone, a natural FXR antagonist.
Description: Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
Study: NCT00331500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine Hydrochloride Ophthalmic Solution Vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT04226794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a-tDCS
Description: Anodal Transcranial direct current stimulation (tDCS) stimulation. Anode will be allocated at DLPFC right and cathode at DLPFC left. The stimulation will occur for 20 min in the intensity of 2 milliampere (mA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Presentation delivered through video clip during 20 minutes based on Cognitive Behavioral Therapy interventions

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: a-tDCS and nutritional counseling
Description: a-tDCS + Nutritional Counseling

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: s-tDCS and nutritional counseling
Description: s-tDCS + Nutritional Counseling
Study: NCT04508660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-400
Description: BID application